Subarachnoid Hemorrhage, SpontaneousMEASURENCT07482124
Multicenter Registry of Patients With Subarachnoid Hemorrhage
An observational study of Subarachnoid Hemorrhage, Spontaneous, run by UMC Utrecht at 9 sites in Netherlands.
Trial summary
The purpose of this registry is to collect detailed information on the characteristics, treatment, and outcomes of patients with a subarachnoid hemorrhage. This information will enable research aimed at improving the safety and effectiveness of current and future treatments. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Subarachnoid Hemorrhage, Spontaneous
- What is being tested?
- None, observational study
- How many people
- 1,000 participants
- Where
- 9 sitesNetherlands
- Study dates
- 12 Feb 2024to 1 Feb 2028
- How long will I take part?
- 18 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients with spontaneous subarachnoid hemorrhage
Who may be able to join
- Age ≥ 18 years
- Spontaneous subarachnoid hemorrhage with blood in the basal cisterns and/or major fissures on non-contrast head computed tomography (CT), or xanthochromia of cerebrospinal fluid confirmed by spectrophotometric analysis.
- Eligible etiologies/patterns:
- Aneurysmal SAH
- SAH from other intracranial vascular malformation (e.g. AVM, dural AVF)
- Perimesencephalic SAH
- Non-perimesencephalic angiogram negative SAH
- SAH from intracranial artery dissection
Who cannot join
- Traumatic, neoplastic, infection related (except mycotic aneurysms), or iatrogenic SAH
- Isolated convexity SAH
Trial locations and contacts
9 sites in 1 country. Contact the study team or a site near you to ask about taking part.
9 sites in 1 country
Netherlands9 sites, 9 recruiting
- Recruiting
Amsterdam University Medical Center
Amsterdam, North Holland, 1105AZ
D. Verbaan, PhD, +31205669111, d.verbaan@amsterdamumc.nl
- Recruiting
University Medical Center Groningen
Groningen, Provincie Groningen, 9713 GZ
J.M.C. van Dijk, MD, PhD, +31503616161, j.m.c.van.dijk@umcg.nl
- Recruiting
Maastricht University Medical Center+
Maastricht, Limburg, 6229 HX
R.H.L. Haeren, MD, PhD, +31433876543, roel.haeren@mumc.nl
- Recruiting
Radboud University Medical Center
Nijmegen, Gelderland, 6525 GA
H.D. Boogaarts, MD, PhD, +31243611111, jeroen.boogaarts@radboudumc.nl
- Recruiting
Erasmus University Medical Center
Rotterdam, South Holland, 3015 GD
V. Volovici, MD, PhD, +31107040704, v.volovici@erasmusmc.nl
- Recruiting
Haaglanden Medical Center
The Hague, South Holland, 2512 VA
W.A. Moojen, MD, PhD, +31889797900, w.moojen@haaglandenmc.nl
- Recruiting
Elisabeth-Tweesteden Hospital
Tilburg, North Brabant, 5022GC
P.J.P. Nachtergaele, MD, PhD, +31132210000, p.nachtergaele@etz.nl
- Recruiting
Utrecht University Medical Center
Utrecht, Utrecht, 3584 CX
M.D.I. Vergouwen, MD, PhD, +3188755555, m.d.i.vergouwen@umcutrecht.nl
- Recruiting
Isala
Zwolle, Overijssel, 8025 AB
M. Podlogar, MD, PhD, +31886245000, m.podlogar@isala.nl
About this study
The purpose of this registry is to collect detailed information on the characteristics, treatment, and outcomes of patients with a subarachnoid hemorrhage. This information will enable research aimed at improving the safety and effectiveness of current and future treatments. By studying these data, the investigators aim to identify which treatment strategies offer the best results and which factors are most important in the care of patients with a subarachnoid hemorrhage. The knowledge gained from this research will help improve patient care in the future.
- Conditions
- Subarachnoid Hemorrhage, Spontaneous
- Being tested
- None, observational study
- Medical subject headings
- Subarachnoid Hemorrhage
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
None, observational studyOther
None, observational study
| Study group | Role | What they receive |
|---|---|---|
| Spontaneous Subarachnoid Hemorrhage | Not described Receives: Other: None, observational study |
What is being measured
The primary outcome is the main question the study is designed to answer.
Modified Rankin Scale (mRS)
The Modified Rankin Scale (mRS) is a scale ranging from 0 to 6, where 0 indicates no symptoms and 6 indicates death. Higher scores indicate a worse outcome.
Measured: 6 months ± 30 days after SAH
Secondary outcomes (14)
modified Rankin Scale (mRS)
The Modified Rankin Scale (mRS) is a scale ranging from 0 to 6, where 0 indicates no symptoms and 6 indicates death. Higher scores indicate a worse outcome.
Measured: 18 months ± 30 days after SAH
Complications related to treatment of the ruptured aneurysm
Measured: Periprocedural
Complications related to SAH
Measured: During registry period (up to 18 months after SAH)
Degree of aneurysm occlusion
For endovascular treatment assessed by the modified Raymond Roy Classification
Measured: Up to 18 months after SAH
Newly found aneurysm or other vascular malformation at additional imaging in patients with non-perimesencephalic primary angiogram negative SAH
Measured: Up to 18 months after SAH
Patient reported outcomes (PROMS): SOS-SAH
The Questionnaire for the Screening of Symptoms in aneurysmal Subarachnoid Hemorrhage (SOS-SAH) is a disease-specific patient-reported outcome measure developed to screen for symptoms in patients after aSAH. It consists of 14 domains: cognitive abilities, hypersensitivity to stimuli, anxiety, depression, fatigue, social roles, personality change, language, vision, taste, smell, hearing, headache, and sexual function. It also includes a proxy measurement for use by family members to assess cognitive functioning and personality changes. External validation of the SOS-SAH is one of the objectives of this registry.
Measured: Up to 18 months ± 30 days after SAH
Patient reported outcomes (PROMS): Stroke Specific Quality of Life scale (SSQoL)
The Stroke Specific Quality of Life scale (SSQoL) assesses health-related quality of life, comprising 49 items across 12 domains. Items are rated on a 5-point Likert scale ranging from "total help needed" to "no help needed." Higher scores indicate better functioning.
Measured: Up to 18 months ± 30 days after SAH
Patient reported outcomes (PROMS): EuroQol 5-Dimension 5-Level (EQ-5D-5L)
The EuroQol 5-Dimension 5-Level (EQ-5D-5L) assesses general health status across five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, each rated on a 5-level severity scale. Three scoring methods are used: (1) the EQ-VAS, a Visual Analogue Scale ranging from 0 to 100 where higher scores indicate better self-rated health; (2) the EQ-5D-5L health state, coded as a 5-digit number ranging from 11111 (full health) to 55555 (worst health); and (3) the EQ-5D-5L index value, calculated using the Dutch tariff, where higher scores indicate better health-related quality of life.
Measured: Up to 18 months ± 30 days after SAH
Patient reported outcomes (PROMS): Hospital Anxiety and Depression Scale (HADS)
The Hospital Anxiety and Depression Scale (HADS) is a 14-item instrument comprising two subscales: one for anxiety and one for depression. Each subscale ranges from 0 to 21. Higher scores indicate greater symptom severity.
Measured: Up to 18 months ± 30 days after SAH
Patient reported outcomes (PROMS): The Cognition scale of the CheckList for Cognitive and Emotional consequences following stroke (CLCE-C)
The Cognition scale of the CheckList for Cognitive and Emotional consequences following stroke (CLCE-C) is an instrument for identifying cognitive problems after stroke. It consists of 13 items addressing cognitive complaints, for each of which the respondent indicates whether the complaint is present or absent. The total score ranges from 0 to 13, where higher scores indicate more cognitive and emotional complaints.
Measured: Up to 18 months ± 30 days after SAH
Patient reported outcomes (PROMS): iMTA Medical Consumption Questionnaire (iMCQ)
The iMTA Medical Consumption Questionnaire (iMCQ) is a generic instrument that measures medical consumption, including hospitalization days, contacts with health care providers, and medication use.
Measured: Up to 18 months ± 30 days after SAH
Patient reported outcomes (PROMS): iMTA Productivity Cost Questionnaire (iPCQ)
The iMTA Productivity Cost Questionnaire (iPCQ) is a generic instrument designed to measure health-related productivity losses in paid and unpaid work.
Measured: Up to 18 months ± 30 days after SAH
Patient reported outcomes (PROMS): The Cognition scale of the CheckList for Cognitive and Emotional consequences following stroke (CLCE-C)
The Cognition scale of the CheckList for Cognitive and Emotional consequences following stroke (CLCE-C) is an instrument for identifying cognitive problems after stroke. It consists of 15 items addressing cognitive and emotional complaints, for each of which the respondent indicates whether the complaint is present or absent. The total score ranges from 0 to 15, where higher scores indicate more cognitive complaints.
Measured: Up to 18 months ± 30 days after SAH
Amsterdam Cognition Scan (ACS)
The Amsterdam Cognition Scan is a web-based digital cognitive test battery of approximately 60 minutes, consisting of 7 tasks assessing attention, memory, processing speed, executive functioning, and psychomotor speed.
Measured: Up to 18 months ± 30 days after SAH
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Mar 2026
- Study start12 Feb 2024
- Primary completion1 Aug 2026 (estimated)
- Study completion1 Feb 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Subarachnoid Hemorrhage, SpontaneousStudies of the same condition, open and under way.
- More trials run by UMC UtrechtThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,000 participants (estimated)
- Target duration
- 18 Months
Sponsor and investigators
- Lead sponsor
- UMC Utrecht
- Sponsor type
- University, hospital or other
- Collaborators
- Dutch Heart Foundation, The Dutch Brain Foundation, Radboud University Medical Center, Erasmus Medical Center, Maastricht University Medical Center, Elisabeth-TweeSteden Ziekenhuis, Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC), Isala, Medical Center Haaglanden, University Medical Center Groningen
- Responsible party
- Principal investigator, Mervyn Vergouwen, UMC Utrecht
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07482124
- Sponsor's protocol ID
- 23U-0340
- Acronym
- MEASURE
- Status last verified
- Mar 2026
- First submitted
- 9 Mar 2026
- Last updated
- 19 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Upon reasonable request: For each study using the data of this registry, analyses will be performed according to a predefined analysis plan with clearly defined statistical methods. These plans will be prepared prior to data analysis and in accordance with relevant reporting standards, such as the STROBE guideline. All data requests and accompanying statistical analysis plans will be reviewed by an independent research committee affiliated with CONTRAST-2 (the Data Access and Writing Committee) to ensure appropriate use of the registry data.
Study at a glance
From the registry record, last updated by the sponsor on 19 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Multicenter Registry of Patients With Subarachnoid Hemorrhage
- ClinicalTrials.gov ID
- NCT07482124
- Acronym / sponsor ID
- MEASURE / 23U-0340
- Conditions
- Subarachnoid Hemorrhage, Spontaneous
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 1,000 participants (estimated)
- Lead sponsor
- UMC UtrechtUniversity, hospital or other
- Collaborators
- Dutch Heart Foundation, The Dutch Brain Foundation, Radboud University Medical Center, Erasmus Medical Center, Maastricht University Medical Center, Elisabeth-TweeSteden Ziekenhuis, Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC), Isala, Medical Center Haaglanden, University Medical Center Groningen
- Study start
- 12 Feb 2024 (actual)
- Primary completion
- 1 Aug 2026 (estimated)
- Study completion
- 1 Feb 2028 (estimated)
- First posted
- 19 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this registry is to collect detailed information on the characteristics, treatment, and outcomes of patients with a subarachnoid hemorrhage. This information will enable research aimed at improving the safety and effectiveness of current and future treatments. By studying these data, the investigators aim to identify which treatment strategies offer the best results and which factors are most important in the care of patients with a subarachnoid hemorrhage. The knowledge gained from this research will help improve patient care in the future.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 18 Months
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Spontaneous Subarachnoid Hemorrhage | – | Other: None, observational study |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients with spontaneous subarachnoid hemorrhage
Key inclusion criteria (8 listed)
- Age ≥ 18 years
- Spontaneous subarachnoid hemorrhage with blood in the basal cisterns and/or major fissures on non-contrast head computed tomography (CT), or xanthochromia of cerebrospinal fluid confirmed by spectrophotometric analysis.
- Eligible etiologies/patterns:
Key exclusion criteria (2 listed)
- Traumatic, neoplastic, infection related (except mycotic aneurysms), or iatrogenic SAH
- Isolated convexity SAH
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| None, observational studyNone, observational study | Other | Spontaneous Subarachnoid Hemorrhage |
Primary outcome
Modified Rankin Scale (mRS)
Time frame: 6 months ± 30 days after SAH
The Modified Rankin Scale (mRS) is a scale ranging from 0 to 6, where 0 indicates no symptoms and 6 indicates death. Higher scores indicate a worse outcome.
14 secondary outcomes
modified Rankin Scale (mRS)
Time frame: 18 months ± 30 days after SAH
Complications related to treatment of the ruptured aneurysm
Time frame: Periprocedural
Complications related to SAH
Time frame: During registry period (up to 18 months after SAH)
Degree of aneurysm occlusion
Time frame: Up to 18 months after SAH
Newly found aneurysm or other vascular malformation at additional imaging in patients with non-perimesencephalic primary angiogram negative SAH
Time frame: Up to 18 months after SAH
Patient reported outcomes (PROMS): SOS-SAH
Time frame: Up to 18 months ± 30 days after SAH
Patient reported outcomes (PROMS): Stroke Specific Quality of Life scale (SSQoL)
Time frame: Up to 18 months ± 30 days after SAH
Patient reported outcomes (PROMS): EuroQol 5-Dimension 5-Level (EQ-5D-5L)
Time frame: Up to 18 months ± 30 days after SAH
Patient reported outcomes (PROMS): Hospital Anxiety and Depression Scale (HADS)
Time frame: Up to 18 months ± 30 days after SAH
Patient reported outcomes (PROMS): The Cognition scale of the CheckList for Cognitive and Emotional consequences following stroke (CLCE-C)
Time frame: Up to 18 months ± 30 days after SAH
Patient reported outcomes (PROMS): iMTA Medical Consumption Questionnaire (iMCQ)
Time frame: Up to 18 months ± 30 days after SAH
Patient reported outcomes (PROMS): iMTA Productivity Cost Questionnaire (iPCQ)
Time frame: Up to 18 months ± 30 days after SAH
Patient reported outcomes (PROMS): The Cognition scale of the CheckList for Cognitive and Emotional consequences following stroke (CLCE-C)
Time frame: Up to 18 months ± 30 days after SAH
Amsterdam Cognition Scan (ACS)
Time frame: Up to 18 months ± 30 days after SAH
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Mar 2026.
- Individual participant dataSharing planned: No. Upon reasonable request: For each study using the data of this registry, analyses will be performed according to a predefined analysis plan with clearly defined statistical methods. These plans will be prepared prior to data analysis and in accordance with relevant reporting standards, such as the STROBE guideline. All data requests and accompanying statistical analysis plans will be reviewed by an independent research committee affiliated with CONTRAST-2 (the Data Access and Writing Committee) to ensure appropriate use of the registry data.
Related trials for Subarachnoid Hemorrhage, Spontaneous
Recruiting
Early Motor-Cognitive Integrative Training on Cognitive and Motor Performance in Patients With Aneurysmal Subarachnoid Hemorrhage
Subarachnoid Aneurysm Hemorrhage
RecruitingObservational study
Determining the Clinical Impact and Prevalence of Hemorrhagic Subtypes in Perimesencephalic Subarachnoid Hemorrhage
Subarachnoid Hemorrhage, Spontaneous, Subarachnoid Hemorrhage, Aneurysmal
RecruitingPhase 2
Infusion of Lidocaine and Steroids in Middle Meningeal Artery for Pain in Subarachnoid Hemorrhage
Subarachnoid Hemorrhage, Aneurysmal, Headache
Active, not recruiting
Auricular VNS Following Subarachnoid Hemorrhage
Subarachnoid Hemorrhage
RecruitingPhase 2
Evaluation of the Safety and Efficacy of Parecoxib in Patients With Subarachnoid Hemorrhage
Neurological Complication
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
9 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Subarachnoid Hemorrhage, Spontaneous, run by UMC Utrecht at 9 sites in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 19 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 9 sites in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact P.B. van Wijngaarden, MD (+88 755 5555, measure@umcutrecht.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Modified Rankin Scale (mRS) (time frame: 6 months ± 30 days after SAH). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Mar 2026.